Takeda Pharmaceutical set to acquire TiGenix for €520m, enhancing gastroenterology and specialty care offerings

Japanese pharmaceutical giant Takeda Pharmaceutical has announced a proposal to acquire TiGenix, a Belgium-based cell therapy company, for €520 million. This acquisition is aimed at expanding Takeda’s late-stage gastroenterology portfolio and enhancing its presence in the American specialty care market. TiGenix, established in 2000, specializes in the development of novel treatments for serious medical conditions using the anti-inflammatory properties of allogeneic, or donor-derived, stem cells.

Focus on Inflammatory Bowel Disease (IBD)

Takeda’s decision to acquire TiGenix underscores its commitment to addressing the unmet medical needs of patients with Inflammatory Bowel Disease (IBD), for which current treatment options are limited. This acquisition is expected to strengthen Takeda’s offerings in the gastroenterology sector, where it has already established a significant presence.

Enhanced Collaboration and Treatment Development

The acquisition will also build on the existing partnership between Takeda and TiGenix, which includes the development and commercialization of TiGenix’s stem cell therapy, Cx601 (darvadstrocel). This therapy is nearing approval in Europe for treating Crohn’s disease, particularly complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s disease. In December 2016, Cx601 received a recommendation for approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Global Clinical Trials and Future Prospects

A pivotal phase 3 trial is currently underway globally to further assess the efficacy of darvadstrocel. Andrew Plump, Chief Medical and Scientific Officer at Takeda, emphasized the importance of collaboration in developing treatments for fistulizing Crohn’s disease. “Limited treatment options exist today and I believe we can be most effective in serving this population by working in collaboration with partners whose unique skill sets allow us to more efficiently explore innovative approaches, including stem cell therapies,” said Plump.

Unanimous Support and Positive Outlook

The acquisition has received unanimous backing from TiGenix’s board of directors, reflecting a strong belief in the mutual benefits of the merger. Eduardo Bravo, CEO of TiGenix, expressed optimism about the acquisition: “We believe the intended takeover bid of Takeda is a positive step for TiGenix’ security holders and reflects the true value of our dedication to patients over the last few years. Takeda is a patient-centric company that offers the best capabilities and resources to ensure access to Cx601 to patients worldwide.”

The proposed acquisition of TiGenix by Takeda Pharmaceutical not only promises to expand Takeda’s capabilities in gastroenterology and specialty care but also signifies a strategic move to enhance global access to innovative cell therapies, marking a significant step forward in the treatment of complex gastrointestinal disorders.